Log in

NYSE:KDMN - Kadmon Stock Price, Forecast & News

$3.99
-0.07 (-1.72 %)
(As of 03/30/2020 06:08 AM ET)
Today's Range
$3.75
Now: $3.99
$4.10
50-Day Range
$2.44
MA: $4.19
$5.16
52-Week Range
$1.63
Now: $3.99
$5.50
Volume2.60 million shs
Average Volume2.86 million shs
Market Capitalization$637.44 million
P/E RatioN/A
Dividend YieldN/A
Beta2.05
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; KD045, an ROCK inhibitor for the treatment of fibrotic diseases; KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson's disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Zydus Pharmaceuticals USA, Inc.; and Jinghua Pharmaceutical Group Co., Ltd. The company is headquartered in New York, New York.
Read More
Kadmon logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone833-900-5366

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.09 million
Book Value$0.95 per share

Profitability

Net Income$-61,370,000.00
Net Margins-1,204.47%

Miscellaneous

Employees116
Market Cap$637.44 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive KDMN News and Ratings via Email

Sign-up to receive the latest news and ratings for KDMN and its competitors with MarketBeat's FREE daily newsletter.


Kadmon (NYSE:KDMN) Frequently Asked Questions

How has Kadmon's stock been impacted by COVID-19 (Coronavirus)?

Kadmon's stock was trading at $3.48 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KDMN shares have increased by 14.7% and is now trading at $3.99. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Kadmon?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kadmon in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kadmon.

When is Kadmon's next earnings date?

Kadmon is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Kadmon.

How were Kadmon's earnings last quarter?

Kadmon Holdings Inc (NYSE:KDMN) posted its quarterly earnings results on Thursday, March, 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.12. The company had revenue of $4.40 million for the quarter, compared to analysts' expectations of $2.75 million. Kadmon had a negative return on equity of 110.70% and a negative net margin of 1,204.47%. View Kadmon's earnings history.

What price target have analysts set for KDMN?

4 brokerages have issued 12-month price targets for Kadmon's shares. Their forecasts range from $8.00 to $25.00. On average, they expect Kadmon's stock price to reach $13.25 in the next twelve months. This suggests a possible upside of 232.1% from the stock's current price. View analysts' price targets for Kadmon.

Has Kadmon been receiving favorable news coverage?

News articles about KDMN stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Kadmon earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutKadmon.

Who are some of Kadmon's key competitors?

What other stocks do shareholders of Kadmon own?

Who are Kadmon's key executives?

Kadmon's management team includes the following people:
  • Dr. Harlan W. Waksal, Pres, CEO & Director (Age 66)
  • Mr. Steven Meehan, Exec. VP & CFO (Age 54)
  • Mr. Steven N. Gordon, Chief Admin., Compliance & Legal Officer, Exec. VP & Gen. Counsel (Age 51)
  • Ms. Cynthia L. Schwalm, Director (Age 59)
  • Mr. Kyle Carver, Controller & Principal Accounting Officer

When did Kadmon IPO?

(KDMN) raised $101 million in an initial public offering on Wednesday, July 27th 2016. The company issued 5,600,000 shares at a price of $16.00-$20.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

What is Kadmon's stock symbol?

Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."

Who are Kadmon's major shareholders?

Kadmon's stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (11.29%), Boxer Capital LLC (4.79%), State Street Corp (2.67%), Sofinnova Investments Inc. (1.83%), Geode Capital Management LLC (1.45%) and Nuveen Asset Management LLC (1.13%). Company insiders that own Kadmon stock include Cynthia Schwalm, Harlan Waksal and Perceptive Advisors Llc. View institutional ownership trends for Kadmon.

Which institutional investors are selling Kadmon stock?

KDMN stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Goldman Sachs Group Inc., Macquarie Group Ltd., Macquarie Group Ltd., Quantitative Systematic Strategies LLC, Bank of America Corp DE, Algert Global LLC, and Principal Financial Group Inc.. View insider buying and selling activity for Kadmon.

Which institutional investors are buying Kadmon stock?

KDMN stock was bought by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Perceptive Advisors LLC, State Street Corp, Nuveen Asset Management LLC, Schonfeld Strategic Advisors LLC, EAM Global Investors LLC, Panagora Asset Management Inc., and EAM Investors LLC. Company insiders that have bought Kadmon stock in the last two years include Cynthia Schwalm, Harlan Waksal, and Perceptive Advisors Llc. View insider buying and selling activity for Kadmon.

How do I buy shares of Kadmon?

Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kadmon's stock price today?

One share of KDMN stock can currently be purchased for approximately $3.99.

How big of a company is Kadmon?

Kadmon has a market capitalization of $637.44 million and generates $5.09 million in revenue each year. The company earns $-61,370,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. Kadmon employs 116 workers across the globe. View additional information about Kadmon.

What is Kadmon's official website?

The official website for Kadmon is http://www.kadmon.com/.

How can I contact Kadmon?

Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 833-900-5366 or via email at [email protected]


MarketBeat Community Rating for Kadmon (NYSE KDMN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  245 (Vote Outperform)
Underperform Votes:  232 (Vote Underperform)
Total Votes:  477
MarketBeat's community ratings are surveys of what our community members think about Kadmon and other stocks. Vote "Outperform" if you believe KDMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KDMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Featured Article: Call Option Volume

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel